文献速递腹部技术与安全MRUS

非侵入性检查预测MASLD患者肝脏相关事件:系统综述与Meta分析

Non-invasive Tests for the Prediction of Liver-related Events in Patients with MASLD: A Systematic Review and Meta-analysis.
PubMed 文献 · Acad Radiol · 2026-07-22

该系统综述纳入30项研究共67533例MASLD患者,评估非侵入性检查预测肝脏相关事件的能力。VCTE、FIB-4指数和MRE预测肝脏相关事件的汇总C指数分别为0.83、0.82和0.78。现有证据支持FIB-4指数和VCTE作为常规非侵入性预后检查。

要点

  • FIB-4指数与VCTE预测MASLD肝脏相关事件性能良好,可常规用于危险分层。
  • MRE预测证据尚不充分,需更多前瞻性研究验证。
  • VCTE对HCC和死亡风险的预测C指数分别为0.78和0.83。

核心结论

  • FIB-4指数和VCTE测定的肝硬度对MASLD患者肝脏相关事件具有稳健的预后判别能力。
  • 现有证据支持FIB-4指数和VCTE作为常规非侵入性预后检查。
  • MRE的预后表现需要在未来研究中进一步验证。

研究设计与样本

  • 系统综述与Meta分析,检索Cochrane Library、Embase、PubMed和Web of Science,截至2026年1月7日。
  • 共纳入30项研究,涉及67533例MASLD患者。
  • 纳入利用非侵入性检查预测新发肝脏相关事件并报告预后性能的研究。
  • 基于数据集特征进行亚组分析和Meta回归以探索异质性来源,所有合并分析采用随机效应模型。

诊断标准与关键数值

  • VCTE预测新发肝脏相关事件的合并C指数为0.83(95% CI:0.79-0.87)。
  • FIB-4指数预测新发肝脏相关事件的合并C指数为0.82(95% CI:0.78-0.85)。
  • MRE预测新发肝脏相关事件的合并C指数为0.78(95% CI:0.64-0.91)。
  • VCTE预测肝细胞癌的合并C指数为0.78(95% CI:0.70-0.86)。
  • VCTE预测死亡风险的合并C指数为0.83(95% CI:0.76-0.89),FIB-4指数为0.75(95% CI:0.66-0.84)。

临床应用与阅片要点

  • 可将FIB-4指数和VCTE肝硬度作为MASLD患者常规预后分层工具。
  • 报告FIB-4指数和LSM结果时,可提示其对肝脏相关事件、HCC及死亡风险的预测价值。
  • MRE结果用于预后判断时需谨慎,其判别效能证据尚不充分。

局限性

  • 原文未报告具体局限性条目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: While guidelines recommend tests like the FIB-4 index and liver stiffness measurements (LSM) to identify high-risk Metabolic dysfunction-associated steatotic liver disease (MASLD) patients, their actual accuracy in predicting liver-related events (LREs) remains unclear. Here, we systematically evaluate their prognostic performance to better inform clinical decisions.

MATERIALS AND METHODS: We systematically searched Cochrane Library, Embase, PubMed and Web of Science (up to January 7, 2026), to identify studies utilizing non-invasive tests (NITs) for predicting incident LREs and reporting their prognostic performance. Subgroup analyses and meta-regression were performed based on dataset characteristics to explore potential sources of heterogeneity. All pooled analyses were conducted using a random-effects model.

RESULTS: This meta-analysis included a total of 30 studies involving 67,533 patients with MASLD. The results demonstrated that for predicting incident LREs, the pooled C-index for Vibration-Controlled Transient Elastography (VCTE), the FIB-4 index, and Magnetic Resonance Elastography (MRE) were 0.83 (95% CI: 0.79-0.87), 0.82 (95% CI: 0.78-0.85), and 0.78 (95% CI: 0.64-0.91), respectively. In the evaluation of secondary outcomes, the pooled C-index of VCTE for predicting hepatocellular carcinoma (HCC) was 0.78 (95% CI: 0.70-0.86). Regarding mortality risk prediction, the pooled C-index for VCTE and the FIB-4 index were 0.83 (95% CI: 0.76-0.89) and 0.75 (95% CI: 0.66-0.84), respectively.

CONCLUSION: The FIB-4 index and LSM measured by VCTE exhibit robust prognostic discrimination for LREs in MASLD. Existing evidence supports the FIB-4 index and VCTE as routine non-invasive prognostic tests. Furthermore, the prognostic performance of MRE requires additional validation in future research.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wang, Dong, Qian, et al. Non-invasive Tests for the Prediction of Liver-related Events in Patients with MASLD: A Systematic Review and Meta-analysis. Acad Radiol. 2026. PMID: 42481370. doi:10.1016/j.acra.2026.06.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。